News
Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline Momentum
Steve St. Onge, PharmD, MBA appointed Senior Vice President of Corporate…
Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections
Newly established relationship with Cystic Fibrosis Foundation enables…
Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy
COLUMBUS, Ohio – June 1, 2023 – Clarametyx Biosciences, Inc. (“Clarametyx”), a…
Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board
Renowned vaccine R&D expert Dr. Jeffrey Almond joins to advise on…
Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial Pneumonia
COLUMBUS, Ohio – November 30, 2022 – Clarametyx Biosciences Inc.…
Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101
COLUMBUS, Ohio – October 5, 2022 – Clarametyx Biosciences Inc. (“Clarametyx”),…
CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial Infections
Supplemental award extends CARB-X collaboration as the Company advances toward…
Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial Infections
Technology prevents development of bacterial biofilms to allow for rapid…
New Publication in Cell Implicates a Rare Form of DNA Driving Antimicrobial Resistance in Bacterial Biofilms
Critical new insights suggest Z-DNA could represent a novel therapeutic target…
Clarametyx Biosciences Awarded $2.7 Million in Option Funding From CARB-X to Accelerate Novel Technology for Persistent Bacterial Infections
Award expands development resources following completion of $8 million…